CPP-LSP-siRNA (PEG–LMWP–AANL–siRNA; no antibody)
Sequence: VSRRRRGGRRRRRRAANL
siRNA (anti-EGFP; thiol-modified; Cy3/TAMRA labeled variants used for imaging)
| Experiment Id | EXP001976 |
|---|---|
| Paper | Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker me |
| Peptide | CPP-LSP-siRNA (PEG–LMWP–AANL–siRNA; no antibody) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 100 nM siRNA for all transfection groups (24 h treatment + 72 h incubation before readout). |
| Mixing Ratio | Covalent CPP–siRNA conjugate. |
| Formulation Format | Covalent CPP–siRNA conjugate |
| Formulation Components | PEG–LMWP–AANL–anti-EGFP siRNA conjugate. |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HCT116-EGFP (EGFP stable transfectant human colon cancer cells) |
| Animal Model | |
| Administration Route | |
| Output Type | In vitro functional RNA effect (EGFP silencing) by confocal + western blot |
| Output Value | ~64.2% EGFP silencing (western blot). |
| Output Units | |
| Output Notes | Better than noncovalent CPP/siRNA physical mixture; less than ARC. |
| Toxicity Notes | |
| Curation Notes |